Background
Traditional use of placebo in research and clinical practice
Open-label placebo
The current study
Primary areas of interest
Replication and expansion of previous findings
Comparing OLP, DBP, and NTC
Secondary areas of interest
Genetic predictors of placebo response
Psychological predictors
Qualitative interviews
Nested peppermint oil study
Methods/design
Subject selection
Inclusion/exclusion criteria
Inclusion |
1. Provide signed and dated informed consent and understand the nature of the study sufficiently to allow completion of all study assessments |
2. Be ambulatory, community dwelling, 18 to 80 years, inclusive |
3. Meet Rome IV diagnostic criteria for IBS |
4. Have IBS of at least moderate severity, i.e., have a score on the IBS-SSS of >175 (0–500) at the baseline visit* |
5. If the patient is on medications which affect the gastrointestinal tract or visceral sensation (e.g., tricyclic antidepressants, fiber, antispasmodics, etc.), they must be on a stable dose for at least 1 month prior to entering the study and for the duration of the study* |
*Participants will be allowed to rescreen once if they do not meet inclusion criteria #4 or #5 at the initial screening visit |
Exclusion |
1. Self-reported pregnancy or planned pregnancy within the next 2 months |
2. Have an established diagnosis of any concomitant bowel disturbance that would interfere with the assessment of efficacy or safety in the study (e.g., Hirschsprung’s disease, diverticulitis, colonic ischemia) |
3. Report warning symptoms (e.g., rectal bleeding, weight loss >10%, iron deficiency anemia, etc.) otherwise not explained |
4. Have undergone previous abdominal surgery to the intestines (with the exception of uncomplicated appendectomy, cholecystectomy, hysterectomy, or polypectomy >6 months prior to enrollment) |
5. Have a history of drug, excluding nicotine or caffeine, or alcohol abuse within 2 years of entry into the study |
6. Exhibit abnormalities on physical examination, unless judged to be clinically insignificant by the investigator. Such cases will be noted |
7. Current, within the past 30 days, therapeutic use of enteric-coated peppermint oil for the treatment of IBS |
8. Known or suspected peppermint or soybean oil allergy |
9. Severe acid reflux (>3 episodes of heartburn or regurgitation per day on average over a week) |
10. Inability to speak or read English |
11. Unable or unwilling to cooperate with the study protocol or considered by the investigator to be unsuitable for the study |
Study interventions
The pills: placebo and peppermint oil softgels
The setting: interactions with clinicians and study staff
Open-label placebo |
Interaction is geared toward making participants comfortable taking open-label placebo and reducing negative feelings about placebo. Specifically, patients will be told the following four points: |
1. In clinical trials, IBS patients treated with placebos often improve nearly as much as patients on active medication |
2. In order to reduce concern that that any placebo effect a participant might experience is “all in the head,” classical conditioning (“like Pavlov’s dogs”) will be suggested as a possible mechanism to explain how such self-healing can happen automatically |
3. To suspend disbelief and encourage an open mind about the effectiveness of the treatment, patients will be told that positive expectations may be helpful, but it is normal to have doubts about open-label placebo. We can understand why patients might think the study is unusual |
4. To encourage adherence, patients will be told that it is most important to take the pills faithfully. Research shows that patients who are more adherent – even to placebo – improve more than those who are less adherent |
5. Participants are provided with reassurance that they may not notice changes right away. They are informed that some people respond to placebo “gradually” and others respond “quickly” and that this varies across individuals |
Double-blind placebo and double-blind peppermint oil |
1. Provide rationale for doing a double-blind experiment and the principle of equipoise |
2. Provide a rationale for why peppermint oil might be effective: “Peppermint oil has been used for many years to ‘soothe’ the GI tract and is known to reduce contractions or spasms in the GI tract” |
3. Explain that peppermint oil in IBS has never been tested in the USA |
4. Provide a rationale for why placebo might be effective: “In early clinical trials IBS patients treated with placebos often improve nearly as much as patients on active medication” |
5. Participants are provided with reassurance that they may not notice changes right away. They are informed that some people respond to placebo “gradually” and others respond “quickly” and that this varies across individuals |
No-treatment control |
1. Explain the importance of this research to develop effective treatments for IBS |
2. Explain that it is critical to measure the normal waxing and waning of IBS symptoms in the no-treatment control group in order to understand the placebo and peppermint effects detected in the other arms of the study |
3. Highlight the importance of not changing anything that they are regularly doing for the IBS during the trial |
4. Explain that the study physician will provide some specific suggestions and options at the end of the trial |
Culture of the trial
Study timeline
Measures
Scale | Description |
---|---|
Primary outcome measure | |
Irritable Bowel Symptom Severity Scale (IBS-SSS) | This 5-item questionnaire provides a simple way to scale IBS symptoms and the progress of the disease. Items consider pain, distension, bowel dysfunction, and quality of life/global wellbeing. Scores show good reliability and sensitivity to change |
Secondary outcome measures | |
Symptom evaluation | |
IBS-Adequate Relief | A single yes/no question makes up this simple global measure of symptom relief in the past week |
IBS-Global Improvement | A single question provides a measure of improvement in the past week using a 7-point scale |
Daily Symptom Diary | Questions regarding subject symptoms will be completed daily for the 7-day period prior to visit 2 and visit 3 |
Quality of life | |
Short Form-12 Health Survey (SF-12) | This 12-item scale measures emotional and physical health and wellbeing |
Psychosocial | |
Patient Health Questionnaire-8 (PHQ-8) | An 8-item scale that is used as a diagnostic and severity measure for depressive disorders in clinical studies |
Generalized Anxiety Disorder-7 (GAD-7) | A 7-item scale that is used as a diagnostic and severity measure for anxiety disorders in clinical practice and research |
Visceral Sensitivity Index | A 15-item measure of gastrointestinal symptom-specific anxiety |
Pain Catastrophizing Scale | A scale that measures the tendency to magnify or exaggerate the seriousness of pain sensations |
Five Factor Inventory | A 60-item instrument that measures the “Big Five” dimensions of personality |
Interpersonal Support Evaluation List | Designed to measure perceptions of social support among individuals in the general population |
Balanced Inventory of Desirable Reach | Describes the tendency of respondents to answer questions that will be viewed favorably by others |
Patient experience | |
Consultation and Relational Empathy Measure | Assesses physician empathy and relational skills on 10 ordinal items, which are then summed |
Expectancy Question | “If I receive placebo/peppermint oil/no additional treatment, I expect my IBS symptoms to be: “(numerical rating scale running from zero “not improved at all” to 100 “completely improved”) |